NIOX MINO^® – the convenient and non-invasive way to monitor patients’ asthma and optimize treatment – is now reimbursable in the U.S. through CPT code 95012 as it is 510(k) cleared for market use by the U.S. Food and Drug Administration (FDA). The CPT code only applies to FDA-cleared devices (currently NIOX, NIOX Flex and NIOX MINO).

NIOX MINO is a cost-effective instrument that measures the inflammation underlying asthma symptoms. NIOX MINO provides added utility and simplicity for the clinic by providing accurate, rapid, real-time NO measurements for adult and pediatric patients.

Reimbursement guide coming soon.

Aerocrine ©